Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
AimovigⓇ - CGRP receptor antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT03867201 DRAGON (CAMG334A2304)
Migraine
Phase 3
550
Change from baseline in monthly migraine days during the last 4 weeks of the 12-
week treatment period
Subcutaneous injection of AMG334 (erenumab) 70 mg
Subcutaneous injection of placebo
Adult chronic migraine patients
Double-blind FIR for 100% of pts 2021; Q4 2021(actual)
Extension (open-label): 2024
Planned in H2-2022 for double-blind phase and H1-2025 for open-label extension
phase
96 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation